Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients

TPF (docetaxel, cisplatin, fluorouracil) is the standard chemotherapy used for induction in locally advanced head and neck squamous cell carcinoma (LAHNSCC). Its toxicity limits it to younger patients with good functional status and without significant comorbidity. Since modified TPF (mTPF) demonstr...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Fayette, Jérôme, Fontaine-Delaruelle, Clara, Ambrun, Alexis, Daveau, Clémentine, Poupart, Marc, Ramade, Antoine, Zrounba, Philippe, Neidhardt, Eve-Marie, Péron, Julien, Diallo, Alpha, Céruse, Philippe
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2016
Sujets:
Clinical Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5095077/
https://ncbi.nlm.nih.gov/pubmed/27119503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8934
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires